$8.78
-0.28 (-3.04%)
DJT News8 articles
Suspicious Oil Trades Precede Trump's Iran Post, Sparking Volatile Rally
Unusual oil and stock futures activity preceded a Trump social media post on Iran talks, fueling a brief but sharp market rally. The gains reversed after Iran denied negotiations, leaving traders questioning the timing.
Markets Rally as Trump Delays Iran Strikes, Easing Oil Shock Fears
Oil prices tumbled sharply while U.S. equity futures rallied after President Trump delayed military action against Iranian energy infrastructure, easing investor concerns over a potential oil supply shock.
Crude Plunges 15% as Trump Hints at Iran Conflict Resolution
Oil prices collapsed nearly 15% Tuesday after Donald Trump indicated the Iran conflict might conclude shortly, erasing Monday's panic-driven surge above $119. G7 ministers deferred tapping emergency reserves.
Oil Plummets 13% as Trump Hints at Iran Conflict Resolution
Oil prices crashed over 13% Tuesday after U.S. President Donald Trump indicated the Iran conflict might conclude shortly, erasing the prior day's surge driven by supply fears. Brent crude fell $12.46 to $86.50 per barrel.
Bitcoin Soars Above $73K on Geopolitical Easing, Trump's Crypto Push
Bitcoin rallied sharply, climbing over 7% to surpass $73,000, fueled by improving risk sentiment and political support for crypto regulation. Related equities and ETFs saw significant inflows.
Crypto Stocks Rally on Trump's Regulatory Push and Bitcoin Surge
Coinbase stock jumped 16% Wednesday, mirroring Bitcoin's 8% surge past $73,800. The rally followed political comments on crypto regulation and a Federal Reserve account approval for Kraken's bank.
IRS Staffing Shortfall May Dampen Economic Boost from Trump's Tax Refund Surge
Taxpayers are poised for larger refunds in 2026 due to new legislation, but IRS workforce reductions could delay payments and limit the anticipated consumer spending lift.
AstraZeneca Shares Hold Ground Ahead of Key Earnings, TrumpRx Pricing Initiative Looms
AstraZeneca shares edged higher ahead of its full-year results, with 2026 guidance and U.S. drug pricing pressures in focus. The stock closed up 0.9% in London and 3.2% in New York.